Private Capital Advisors Inc. Purchases New Position in Dermira Inc (DERM)

Private Capital Advisors Inc. purchased a new position in shares of Dermira Inc (NASDAQ:DERM) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 35,000 shares of the biopharmaceutical company’s stock, valued at approximately $973,000.

A number of other institutional investors and hedge funds have also made changes to their positions in DERM. Point72 Asset Management L.P. raised its stake in shares of Dermira by 621.8% in the third quarter. Point72 Asset Management L.P. now owns 712,904 shares of the biopharmaceutical company’s stock valued at $19,248,000 after acquiring an additional 614,138 shares during the last quarter. BlackRock Inc. raised its stake in shares of Dermira by 15.6% in the second quarter. BlackRock Inc. now owns 3,922,253 shares of the biopharmaceutical company’s stock valued at $114,294,000 after acquiring an additional 529,405 shares during the last quarter. Voya Investment Management LLC raised its stake in shares of Dermira by 61.4% in the second quarter. Voya Investment Management LLC now owns 1,227,948 shares of the biopharmaceutical company’s stock valued at $35,783,000 after acquiring an additional 467,356 shares during the last quarter. State Street Corp raised its stake in shares of Dermira by 38.4% in the second quarter. State Street Corp now owns 821,748 shares of the biopharmaceutical company’s stock valued at $23,946,000 after acquiring an additional 228,093 shares during the last quarter. Finally, Tekla Capital Management LLC raised its stake in shares of Dermira by 134.2% in the second quarter. Tekla Capital Management LLC now owns 386,900 shares of the biopharmaceutical company’s stock valued at $11,274,000 after acquiring an additional 221,700 shares during the last quarter. Hedge funds and other institutional investors own 99.47% of the company’s stock.

DERM has been the subject of a number of research analyst reports. Cantor Fitzgerald set a $45.00 target price on shares of Dermira and gave the company a “buy” rating in a research note on Wednesday, November 29th. Needham & Company LLC reissued a “buy” rating and issued a $43.00 price target (down previously from $46.00) on shares of Dermira in a report on Tuesday, November 7th. BidaskClub raised shares of Dermira from a “hold” rating to a “buy” rating in a report on Wednesday, December 20th. Guggenheim reaffirmed a “buy” rating and set a $30.00 target price on shares of Dermira in a report on Thursday, December 14th. Finally, Mizuho lowered their target price on shares of Dermira from $43.00 to $39.00 and set a “buy” rating for the company in a report on Tuesday, December 12th. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $41.00.

In other Dermira news, insider Eugene A. Bauer sold 3,000 shares of Dermira stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $27.07, for a total transaction of $81,210.00. Following the completion of the sale, the insider now owns 5,802 shares of the company’s stock, valued at approximately $157,060.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Thomas G. Wiggans sold 5,000 shares of Dermira stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $27.52, for a total transaction of $137,600.00. The disclosure for this sale can be found here. Insiders have sold a total of 36,258 shares of company stock valued at $985,873 in the last ninety days. Company insiders own 13.30% of the company’s stock.

Dermira Inc (NASDAQ DERM) traded up $0.74 on Friday, reaching $27.44. 1,060,000 shares of the company’s stock were exchanged, compared to its average volume of 597,006. The company has a quick ratio of 4.68, a current ratio of 4.68 and a debt-to-equity ratio of 1.40. Dermira Inc has a 12-month low of $21.35 and a 12-month high of $38.75. The firm has a market cap of $1,140.00, a price-to-earnings ratio of -4.40 and a beta of 0.80.

TRADEMARK VIOLATION NOTICE: “Private Capital Advisors Inc. Purchases New Position in Dermira Inc (DERM)” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.com-unik.info/2018/01/12/private-capital-advisors-inc-purchases-new-position-in-dermira-inc-derm.html.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Want to see what other hedge funds are holding DERM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dermira Inc (NASDAQ:DERM).

Institutional Ownership by Quarter for Dermira (NASDAQ:DERM)

What are top analysts saying about Dermira? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dermira and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit